Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 8/20 | 0.68 |
| ▸ | F2 | P00734 | 1/20 | 0.61 |
| ▸ | AVPR1A | P37288 | 7/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | PLG | P00747 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6435876 | 0.92 | AVPR1B (0.69) | AVPR1BF2AVPR1APOLBPLG | |
| SCHEMBL28570961 | 0.81 | CTSL (0.58) | AVPR1BF2AVPR1APLG | |
| SCHEMBL28559473 | 0.81 | CTSL (0.58) | AVPR1BF2AVPR1APLG | |
| SCHEMBL28562286 | 0.81 | CTSL (0.58) | AVPR1BF2AVPR1APLG | |
| SCHEMBL28565573 | 0.81 | CTSL (0.58) | AVPR1BF2AVPR1APLG | |
| SCHEMBL28559474 | 0.81 | CTSL (0.58) | AVPR1BF2AVPR1APLG | |
| SCHEMBL6387247 | 0.80 | F2 (0.53) | AVPR1BF2AVPR1A | |
| SCHEMBL6387250 | 0.80 | F2 (0.53) | AVPR1BF2AVPR1A | |
| SCHEMBL6390714 | 0.79 | AVPR1B (0.53) | AVPR1BF2AVPR1APLG | |
| SCHEMBL6390711 | 0.79 | AVPR1B (0.53) | AVPR1BF2AVPR1APLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936620-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| US-6887877-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-05-03 | — | — | US | disclosed |
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | SHIRE BIOCHEM INC. (CA) | 2003-12-11 | — | — | US | disclosed |
| US-20030166647-A1 | Barbituric acid derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166647-A1 | Barbituric acid derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and/or matrix metalloproteinases | TNF, MMP1, ADAMTS1 | AVPR1B 1279/4885F2 865/4885AVPR1A 1325/4885 |
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | HAVCR2, ZC3HAV1, MAVS | AVPR1B 2300/4885F2 691/4885AVPR1A 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.